Outcomes of Differentiated Models of Antiretroviral Treatment (ART) Provision
NCT ID: NCT03438370
Last Updated: 2018-02-19
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
UNKNOWN
Clinical Phase
NA
Total Enrollment
5760 participants
Study Classification
INTERVENTIONAL
Study Start Date
2017-08-07
Study Completion Date
2019-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The aim of this study is to evalulate the effectiveness and cost-effectiveness of three models of ART provision for stable ART patients. The objectives are to measure patient retention, virological suppression, provider and patient costs, cost-effectiveness, and patient acceptability amongst stable patients who receive ART at intervals of three and six months within community distribution models, and to compare these to patients who receive ART directly from the clinic at three month intervals.
Methods
A prospective, parallel, cluster-randomized non-inferiority trial with three study arms will be conducted. 30 Clusters (sites) will be randomized in strata according to geographic location (urban and rural) to the 3 study arms as follows:
* Control arm: sites at which patients will receive three monthly ART supply at the facility (arm 3MF).
* Intervention arm 1: sites at which patients will receive three monthly ART supply in CAGs (arm 3MC)
* Intervention arm 2: sites at which patients will receive six monthly ART supply in the community by a healthcare worker (arm 6MCD).
The study population will consist of stable, HIV-infected adults who have received first-line ART for at least six months, who have a viral load \<1000 copies/ml at baseline, and who provide informed consent for inclusion in the study. An average of 192 participants from each study site will be included, with a total sample size of approximately 5760 participants.
The primary outcome is retention in care defined as the proportion of patients remaining in care 12 months after study enrolment, with the hypothesis that patient retention within the intervention arms will be non-inferior compared to the control arm. Retention in care will also be compared between the three arms after 24 months.
The secondary outcomes are:
* Viral suppression: defined as the proportion of patients with virological suppression (\<1000 copies/ml) 12 and 24 months after study enrolment;
* Cost of providing ART: defined as the cost per patient of providing ART in each of the three arms (from a provider perspective);
* Cost of retaining a patient: defined as the provider cost per patient retained and provider cost per patient retained with virological suppression in each of the three arms, and the incremental cost-effectiveness ratio for the comparative arms.
Methods
A prospective, parallel, cluster-randomized non-inferiority trial with three study arms will be conducted. 30 Clusters (sites) will be randomized in strata according to geographic location (urban and rural) to the 3 study arms as follows:
* Control arm: sites at which patients will receive three monthly ART supply at the facility (arm 3MF).
* Intervention arm 1: sites at which patients will receive three monthly ART supply in CAGs (arm 3MC)
* Intervention arm 2: sites at which patients will receive six monthly ART supply in the community by a healthcare worker (arm 6MCD).
The study population will consist of stable, HIV-infected adults who have received first-line ART for at least six months, who have a viral load \<1000 copies/ml at baseline, and who provide informed consent for inclusion in the study. An average of 192 participants from each study site will be included, with a total sample size of approximately 5760 participants.
The primary outcome is retention in care defined as the proportion of patients remaining in care 12 months after study enrolment, with the hypothesis that patient retention within the intervention arms will be non-inferior compared to the control arm. Retention in care will also be compared between the three arms after 24 months.
The secondary outcomes are:
* Viral suppression: defined as the proportion of patients with virological suppression (\<1000 copies/ml) 12 and 24 months after study enrolment;
* Cost of providing ART: defined as the cost per patient of providing ART in each of the three arms (from a provider perspective);
* Cost of retaining a patient: defined as the provider cost per patient retained and provider cost per patient retained with virological suppression in each of the three arms, and the incremental cost-effectiveness ratio for the comparative arms.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy and Safety of Single Versus Double Ritonavir-boosted Protease Inhibitor (PI)-Based Antiretroviral Therapy (ART) Regimens
NCT00886990
HIV Infection
HIV Infections
COMPLETED
Evaluation of a Simplified Strategy for the Long-term Management of HIV Infection (Simpl'HIV)
NCT03160105
HIV-1-infection
Antiretroviral Therapy
Maintenance Therapy
COMPLETED
PHASE4
Study Evaluating the Efficacy of a Reduced Dose Atazanavir in HIV-1-infected Patients
NCT02473328
HIV-1 Infection
COMPLETED
PHASE2
Simplification to Atazanavir/Ritonavir + Lamivudine as Maintenance Therapy
NCT01307488
HIV Infection
COMPLETED
PHASE4
Comparing PI-Based to a nNRTI-based ART for Clearance of Plasmodium Falciparum Parasitemia in HIV-Infected
NCT01632891
HIV-1 Infection
Pf Subclinical Parasitemia
COMPLETED
PHASE1/PHASE2
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Background In 2015, sub-Saharan Africa was still the region most affected by the HIV epidemic, with 25.6 (23.1-28.5) million people living with HIV in 2015. It is estimated that 42% of all people living with HIV (PLHIV) in Lesotho were receiving ART by 2015.The United States Government's President's Emergency Plan for AIDS Relief (PEPFAR) has adopted the goals of 90-90-90 from UNAIDS, and is supporting a swift implementation of the new World Health Organization'sTest and Start guidelines.With these goals, PEPFAR also sets out to reduce new infections by 75% and to attain zero discrimination and stigma for all PLHIV.
To assist countries to reach the goal of universal coverage, EQUIP Innovation for health (a new field support award from the USAID Office of HIV and AIDS that supports innovations in HIV clinical and community-based HIV treatment related services) is evaluating communitybased care, treatment and support models to create an enabling environment for massive scale-up of ART delivery and adherence support. Based on this background, EQUIP and and Elizabeth Glaser Pediatric AIDS Foundation (EGPAF) propose to conduct operational research that seeks to understand and measure the effectiveness of implementing a package of services that include multi-month dispensing (MMD) of ART drugs, Community ART distribution models through Community ART Groups (CAGs) and Community Distribution points and routine viral load monitoring of stable patients in communities of PEPFAR/USAID Lesotho scale-up districts.
The aim of this study is to evalulate the effectiveness and cost-effectiveness of three models of ART provision for stable ART patients. The objectives are to measure patient retention, virological suppression, provider and patient costs, cost-effectiveness, and patient acceptability amongst stable patients who receive ART at intervals of three and six months within community distribution models, and to compare these to patients who receive ART directly from the clinic at three month intervals.
Methods
A prospective, parallel, cluster-randomized non-inferiority trial with three study arms will be conducted. 30 Clusters (sites) will be randomized in strata according to geographic location (urban and rural) to the 3 study arms as follows:
* Control arm: sites at which patients will receive three monthly ART supply at the facility (arm 3MF).
* Intervention arm 1: sites at which patients will receive three monthly ART supply in CAGs (arm 3MC)
* Intervention arm 2: sites at which patients will receive six monthly ART supply in the community by a healthcare worker (arm 6MCD).
Sites for inclusion in the study will be selected at which it is deemed to be feasible to implement multi-month dispensing of ART in the community.
The study population will consist of stable, HIV-infected adults who have received first-line ART for at least six months, who have a viral load \<1000 copies/ml at baseline, and who provide informed consent for inclusion in the study. An average of 192 participants from each study site will be included, with a total sample size of approximately 5760 participants. For those sites randomized to the 3MC arm, enrolled participants will be part of a CAG for the duration of the study. For those sites randomized to the 6MCD arm, enrolled participants will be dispensed a 6-month supply of ART in the community by a healthcare worker in between their annual clinical assessments. All participants will have a clinical assessment and viral load testing at the clinic at least annually, and participants will be followed-up for 24 months after enrolment.
The primary outcome is retention in care defined as the proportion of patients remaining in care 12 months after study enrolment, with the hypothesis that patient retention within the intervention arms will be non-inferior compared to the control arm. Retention in care will also be compared between the three arms after 24 months.
The secondary outcomes are:
* Viral suppression: defined as the proportion of patients with virological suppression (\<1000 copies/ml) 12 and 24 months after study enrolment;
* Cost of providing ART: defined as the cost per patient of providing ART in each of the three arms (from a provider perspective);
* Cost of retaining a patient: defined as the provider cost per patient retained and provider cost per patient retained with virological suppression in each of the three arms, and the incremental cost-effectiveness ratio for the comparative arms.
Qualitative research will include assessing the acceptability of multi-month dispensing of ART within CAGs and the community from both a patient and healthcare provider perspective. Costs to patients will be compared between the three arms from data derived from patient surveys. In addition, indicators of potential facility level decongestion will be compared between arms, which will include the median facility patient waiting time and average monthly number of patients newly initiated on ART, with data derived from site surveys and routine facility-level data.
This study will follow the ethical considerations specified by the Lesotho National Health Research and Ethics Committee.
The results of the study are expected to inform health policy both nationally and regionally regarding the effectiveness of implementing a package of services consisting of MMD within CAGs and community distribution together with viral load monitoring for stable ART patients.
To assist countries to reach the goal of universal coverage, EQUIP Innovation for health (a new field support award from the USAID Office of HIV and AIDS that supports innovations in HIV clinical and community-based HIV treatment related services) is evaluating communitybased care, treatment and support models to create an enabling environment for massive scale-up of ART delivery and adherence support. Based on this background, EQUIP and and Elizabeth Glaser Pediatric AIDS Foundation (EGPAF) propose to conduct operational research that seeks to understand and measure the effectiveness of implementing a package of services that include multi-month dispensing (MMD) of ART drugs, Community ART distribution models through Community ART Groups (CAGs) and Community Distribution points and routine viral load monitoring of stable patients in communities of PEPFAR/USAID Lesotho scale-up districts.
The aim of this study is to evalulate the effectiveness and cost-effectiveness of three models of ART provision for stable ART patients. The objectives are to measure patient retention, virological suppression, provider and patient costs, cost-effectiveness, and patient acceptability amongst stable patients who receive ART at intervals of three and six months within community distribution models, and to compare these to patients who receive ART directly from the clinic at three month intervals.
Methods
A prospective, parallel, cluster-randomized non-inferiority trial with three study arms will be conducted. 30 Clusters (sites) will be randomized in strata according to geographic location (urban and rural) to the 3 study arms as follows:
* Control arm: sites at which patients will receive three monthly ART supply at the facility (arm 3MF).
* Intervention arm 1: sites at which patients will receive three monthly ART supply in CAGs (arm 3MC)
* Intervention arm 2: sites at which patients will receive six monthly ART supply in the community by a healthcare worker (arm 6MCD).
Sites for inclusion in the study will be selected at which it is deemed to be feasible to implement multi-month dispensing of ART in the community.
The study population will consist of stable, HIV-infected adults who have received first-line ART for at least six months, who have a viral load \<1000 copies/ml at baseline, and who provide informed consent for inclusion in the study. An average of 192 participants from each study site will be included, with a total sample size of approximately 5760 participants. For those sites randomized to the 3MC arm, enrolled participants will be part of a CAG for the duration of the study. For those sites randomized to the 6MCD arm, enrolled participants will be dispensed a 6-month supply of ART in the community by a healthcare worker in between their annual clinical assessments. All participants will have a clinical assessment and viral load testing at the clinic at least annually, and participants will be followed-up for 24 months after enrolment.
The primary outcome is retention in care defined as the proportion of patients remaining in care 12 months after study enrolment, with the hypothesis that patient retention within the intervention arms will be non-inferior compared to the control arm. Retention in care will also be compared between the three arms after 24 months.
The secondary outcomes are:
* Viral suppression: defined as the proportion of patients with virological suppression (\<1000 copies/ml) 12 and 24 months after study enrolment;
* Cost of providing ART: defined as the cost per patient of providing ART in each of the three arms (from a provider perspective);
* Cost of retaining a patient: defined as the provider cost per patient retained and provider cost per patient retained with virological suppression in each of the three arms, and the incremental cost-effectiveness ratio for the comparative arms.
Qualitative research will include assessing the acceptability of multi-month dispensing of ART within CAGs and the community from both a patient and healthcare provider perspective. Costs to patients will be compared between the three arms from data derived from patient surveys. In addition, indicators of potential facility level decongestion will be compared between arms, which will include the median facility patient waiting time and average monthly number of patients newly initiated on ART, with data derived from site surveys and routine facility-level data.
This study will follow the ethical considerations specified by the Lesotho National Health Research and Ethics Committee.
The results of the study are expected to inform health policy both nationally and regionally regarding the effectiveness of implementing a package of services consisting of MMD within CAGs and community distribution together with viral load monitoring for stable ART patients.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
HIV/AIDS
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Cluster Randomized Trial comparing three different antiretroviral therapy (ART) dispensing strategies.
Primary Study Purpose
HEALTH_SERVICES_RESEARCH
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Three monthly ART supply at facilities
Sites at which patients will be provided three monthly ART supply at health facilities.
Group Type
NO_INTERVENTION
No interventions assigned to this group
Three monthly ART supply at CAGs
Sites at which patients will be provided three monthly ART supply at Community ART Groups (CAGs).
Group Type
EXPERIMENTAL
Three monthly ART supply at CAGs
Intervention Type
OTHER
Sites where three monthly ART supply will be provided at outreaches
Six monthly ART supply at outreaches
Sites at which patients will be provided six monthly ART supply at Community distribution points or outreaches.
Group Type
EXPERIMENTAL
Six monthly ART supply at outreaches
Intervention Type
OTHER
Sites where six monthly ART will supply will be provided at outreaches
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Three monthly ART supply at CAGs
Sites where three monthly ART supply will be provided at outreaches
Intervention Type
OTHER
Six monthly ART supply at outreaches
Sites where six monthly ART will supply will be provided at outreaches
Intervention Type
OTHER
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* At least 18 years of age and willing and able to provide written informed consent for participation in this study.
* Willing to participate in the multi-month dispensing model that the patient's study site has been randomized to.
* On ART ≥ 6 months with no periods of defaulting from ART since the last viral load result (ART default defined as missing 7 or more consecutive days of ART)
* On first-line ART regimen (substitutions within the first-line regimen prior to the last viral load test are permissible).
* No ARV drug substitutions since the last viral load result \< 1,000 copies per ml
* Plasma or dried-blood spot viral load \< 1,000 copies/ml in a patient who has been on first-line ART for at least 6 months, with viral load drawn within last 12 months of enrollment while patient is receiving ART
* Willing to participate in the multi-month dispensing model that the patient's study site has been randomized to.
* On ART ≥ 6 months with no periods of defaulting from ART since the last viral load result (ART default defined as missing 7 or more consecutive days of ART)
* On first-line ART regimen (substitutions within the first-line regimen prior to the last viral load test are permissible).
* No ARV drug substitutions since the last viral load result \< 1,000 copies per ml
* Plasma or dried-blood spot viral load \< 1,000 copies/ml in a patient who has been on first-line ART for at least 6 months, with viral load drawn within last 12 months of enrollment while patient is receiving ART
Exclusion Criteria
* On second-line ART regimen.
* Patients with co-morbidities requiring facility visits more often than 6 monthly.
* ART substitutions since last VL test.
* Diagnosed with a WHO clinical stage 3 or 4 condition within the past 3 months.
* Pregnant or less than 12 months postpartum and breastfeeding mothers.
* Participating in another study that involves dispensing interval, adherence, or retention or involves receiving medications.
* Patients with co-morbidities requiring facility visits more often than 6 monthly.
* ART substitutions since last VL test.
* Diagnosed with a WHO clinical stage 3 or 4 condition within the past 3 months.
* Pregnant or less than 12 months postpartum and breastfeeding mothers.
* Participating in another study that involves dispensing interval, adherence, or retention or involves receiving medications.
Minimum Eligible Age
18 Years
Maximum Eligible Age
80 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ministry of Health, Lesotho
OTHER_GOV
Sponsor Role
collaborator
United States Agency for International Development (USAID)
FED
Sponsor Role
collaborator
Elizabeth Glaser Pediatric AIDS Foundation
OTHER
Sponsor Role
collaborator
Lesotho Network of AIDS Services Organizations
UNKNOWN
Sponsor Role
collaborator
National Drugs Service Organisation of Lesotho
UNKNOWN
Sponsor Role
collaborator
Chemonics
UNKNOWN
Sponsor Role
collaborator
Equip, Lesotho
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Iyiola Faturiyele, MBChB, MPH
Role: PRINCIPAL_INVESTIGATOR
Member, Southern Africa HIV Clinician Society, Johannesburg, South Africa, 2010-present
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ha Tlali
Maseru, , Lesotho
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
Lesotho
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
WHO. HIV/AIDS: Fact sheet. 2016 [cited 2016 12/12/2016].
Reference Type
BACKGROUND
The Joint United Nations Programme on HIV / AIDS (UNAIDS). Project update. Pac AIDS Alert Bull. 1999;(18):15-6.
Reference Type
BACKGROUND
Government of Lesotho. National guidelines on the use of antiretroviral therapy for HIV prevention and treatment. In: MOH, editor.2014
Reference Type
BACKGROUND
MOH Lesotho. GLOBAL AIDS RESPONSE PROGRESS REPORT 2015. 2015 Reporting Period: January - December 2014.
Reference Type
BACKGROUND
Guideline on When to Start Antiretroviral Therapy and on Pre-Exposure Prophylaxis for HIV. Geneva: World Health Organization; 2015 Sep. Available from http://www.ncbi.nlm.nih.gov/books/NBK327115/
Reference Type
BACKGROUND
Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendations for a Public Health Approach. 2nd edition. Geneva: World Health Organization; 2016. Available from http://www.ncbi.nlm.nih.gov/books/NBK374294/
Reference Type
BACKGROUND
Teck R. Reducing frequency of ARV pick-ups for HIV patients stabilised on ARV treatment 2015.
Reference Type
BACKGROUND
Lesotho Go. Lesotho CAG toolkit In: MOH, editor.2015.
Reference Type
BACKGROUND
Joint United Nations Programme on HIV/AIDS (UNAIDS). COMMUNITY-BASED ANTIRETROVIRAL THERAPY DELIVERY. EXPERIENCES OF MÉDECINS SANS FRONTIÈRES. 2015.
Reference Type
BACKGROUND
World Health Organization. Retention in HIV programmes: defining the challenges and identifying solutions: meeting report, 13-15 September 2011. 2012.
Reference Type
BACKGROUND
Bemelmans M, Baert S, Goemaere E, Wilkinson L, Vandendyck M, van Cutsem G, Silva C, Perry S, Szumilin E, Gerstenhaber R, Kalenga L, Biot M, Ford N. Community-supported models of care for people on HIV treatment in sub-Saharan Africa. Trop Med Int Health. 2014 Aug;19(8):968-77. doi: 10.1111/tmi.12332. Epub 2014 May 28.
Reference Type
RESULT
Loeliger KB, Niccolai LM, Mtungwa LN, Moll A, Shenoi SV. Antiretroviral therapy initiation and adherence in rural South Africa: community health workers' perspectives on barriers and facilitators. AIDS Care. 2016 Aug;28(8):982-93. doi: 10.1080/09540121.2016.1164292. Epub 2016 Apr 4.
Reference Type
RESULT
Tiruneh YM, Galarraga O, Genberg B, Wilson IB. Retention in Care among HIV-Infected Adults in Ethiopia, 2005- 2011: A Mixed-Methods Study. PLoS One. 2016 Jun 7;11(6):e0156619. doi: 10.1371/journal.pone.0156619. eCollection 2016.
Reference Type
RESULT
Rasschaert F, Decroo T, Remartinez D, Telfer B, Lessitala F, Biot M, Candrinho B, Van Damme W. Sustainability of a community-based anti-retroviral care delivery model - a qualitative research study in Tete, Mozambique. J Int AIDS Soc. 2014 Oct 6;17(1):18910. doi: 10.7448/IAS.17.1.18910. eCollection 2014.
Reference Type
RESULT
Tuller DM, Bangsberg DR, Senkungu J, Ware NC, Emenyonu N, Weiser SD. Transportation costs impede sustained adherence and access to HAART in a clinic population in southwestern Uganda: a qualitative study. AIDS Behav. 2010 Aug;14(4):778-84. doi: 10.1007/s10461-009-9533-2. Epub 2009 Mar 13.
Reference Type
RESULT
Amanyire G, Wanyenze R, Alamo S, Kwarisiima D, Sunday P, Sebikaari G, Kamya M, Wabwire-Mangen F, Wagner G. Client and provider perspectives of the efficiency and quality of care in the context of rapid scale-up of antiretroviral therapy. AIDS Patient Care STDS. 2010 Nov;24(11):719-27. doi: 10.1089/apc.2010.0108. Epub 2010 Oct 29.
Reference Type
RESULT
Fay H, Baral SD, Trapence G, Motimedi F, Umar E, Iipinge S, Dausab F, Wirtz A, Beyrer C. Stigma, health care access, and HIV knowledge among men who have sex with men in Malawi, Namibia, and Botswana. AIDS Behav. 2011 Aug;15(6):1088-97. doi: 10.1007/s10461-010-9861-2.
Reference Type
RESULT
Rollins NC, Becquet R, Orne-Gliemann J, Phiri S, Hayashi C, Baller A, Shaffer N; INSPIRE Team. Defining and analyzing retention-in-care among pregnant and breastfeeding HIV-infected women: unpacking the data to interpret and improve PMTCT outcomes. J Acquir Immune Defic Syndr. 2014 Nov 1;67 Suppl 2:S150-6. doi: 10.1097/QAI.0000000000000355.
Reference Type
RESULT
Geng EH, Glidden DV, Emenyonu N, Musinguzi N, Bwana MB, Neilands TB, Muyindike W, Yiannoutsos CT, Deeks SG, Bangsberg DR, Martin JN. Tracking a sample of patients lost to follow-up has a major impact on understanding determinants of survival in HIV-infected patients on antiretroviral therapy in Africa. Trop Med Int Health. 2010 Jun;15 Suppl 1(Suppl 1):63-9. doi: 10.1111/j.1365-3156.2010.02507.x.
Reference Type
RESULT
Roy M, Czaicki N, Holmes C, Chavan S, Tsitsi A, Odeny T, Sikazwe I, Padian N, Geng E. Understanding Sustained Retention in HIV/AIDS Care and Treatment: a Synthetic Review. Curr HIV/AIDS Rep. 2016 Jun;13(3):177-85. doi: 10.1007/s11904-016-0317-9.
Reference Type
RESULT
Decroo T, Koole O, Remartinez D, dos Santos N, Dezembro S, Jofrisse M, Rasschaert F, Biot M, Laga M. Four-year retention and risk factors for attrition among members of community ART groups in Tete, Mozambique. Trop Med Int Health. 2014 May;19(5):514-21. doi: 10.1111/tmi.12278. Epub 2014 Feb 12.
Reference Type
RESULT
Marconi VC, Wu B, Hampton J, Ordonez CE, Johnson BA, Singh D, John S, Gordon M, Hare A, Murphy R, Nachega J, Kuritzkes DR, del Rio C, Sunpath H; South Africa Resistance Cohort Study Team Group Authors. Early warning indicators for first-line virologic failure independent of adherence measures in a South African urban clinic. AIDS Patient Care STDS. 2013 Dec;27(12):657-68. doi: 10.1089/apc.2013.0263.
Reference Type
RESULT
Cohen M, Chen Y, McCauley M, Gamble T, Hosseinipour M, Kumarasamy N, et al., editors. Final results of the HPTN 052 randomized controlled trial: antiretroviral therapy prevents HIV transmission. Journal of the International AIDS Society; 2015: INT AIDS SOCIETY AVENUE DE FRANCE 23, GENEVA, 1202, SWITZERLAND.
Reference Type
RESULT
Ndahimana Jd, Riedel DJ, Mwumvaneza M, Sebuhoro D, Uwimbabazi JC, Kubwimana M, Mugabo J, Mulindabigwi A, Kirk C, Kanters S, Forrest JI, Jagodzinski LL, Peel SA, Ribakare M, Redfield RR, Nsanzimana S. Drug resistance mutations after the first 12 months on antiretroviral therapy and determinants of virological failure in Rwanda. Trop Med Int Health. 2016 Jul;21(7):928-35. doi: 10.1111/tmi.12717. Epub 2016 Jun 13.
Reference Type
RESULT
Stadeli KM, Richman DD. Rates of emergence of HIV drug resistance in resource-limited settings: a systematic review. Antivir Ther. 2013;18(1):115-23. doi: 10.3851/IMP2437. Epub 2012 Oct 10.
Reference Type
RESULT
McMahon JH, Elliott JH, Bertagnolio S, Kubiak R, Jordan MR. Viral suppression after 12 months of antiretroviral therapy in low- and middle-income countries: a systematic review. Bull World Health Organ. 2013 May 1;91(5):377-385E. doi: 10.2471/BLT.12.112946. Epub 2013 Feb 21.
Reference Type
RESULT
Ammassari A, Trotta MP, Shalev N, Marconi P, Antinori A. Beyond virological suppression: the role of adherence in the late HAART era. Antivir Ther. 2012;17(5):785-92. doi: 10.3851/IMP2084. Epub 2012 Mar 13.
Reference Type
RESULT
Coker M, Etiebet MA, Chang H, Awwal G, Jumare J, Musa BM, Babashani M, Habib AG, Dakum P, Abimiku AG, Charurat ME, Blattner WA, Eng M, Ndembi N. Socio-Demographic and Adherence Factors Associated with Viral Load Suppression in HIV-Infected Adults Initiating Therapy in Northern Nigeria: A Randomized Controlled Trial of a Peer Support Intervention. Curr HIV Res. 2015;13(4):279-85. doi: 10.2174/1570162x13666150407143838.
Reference Type
RESULT
Fatti G, Shaikh N, Eley B, Grimwood A. Improved virological suppression in children on antiretroviral treatment receiving community-based adherence support: a multicentre cohort study from South Africa. AIDS Care. 2014 Apr;26(4):448-53. doi: 10.1080/09540121.2013.855699. Epub 2013 Nov 11.
Reference Type
RESULT
Ferrand RA, Briggs D, Ferguson J, Penazzato M, Armstrong A, MacPherson P, Ross DA, Kranzer K. Viral suppression in adolescents on antiretroviral treatment: review of the literature and critical appraisal of methodological challenges. Trop Med Int Health. 2016 Mar;21(3):325-33. doi: 10.1111/tmi.12656. Epub 2016 Jan 10.
Reference Type
RESULT
Fairall L, Bachmann MO, Lombard C, Timmerman V, Uebel K, Zwarenstein M, Boulle A, Georgeu D, Colvin CJ, Lewin S, Faris G, Cornick R, Draper B, Tshabalala M, Kotze E, van Vuuren C, Steyn D, Chapman R, Bateman E. Task shifting of antiretroviral treatment from doctors to primary-care nurses in South Africa (STRETCH): a pragmatic, parallel, cluster-randomised trial. Lancet. 2012 Sep 8;380(9845):889-98. doi: 10.1016/S0140-6736(12)60730-2. Epub 2012 Aug 15.
Reference Type
RESULT
Lake S, Kammann E, Klar N, Betensky R. Sample size re-estimation in cluster randomization trials. Stat Med. 2002 May 30;21(10):1337-50. doi: 10.1002/sim.1121.
Reference Type
RESULT
Xu X, Grossetta Nardini HK, Ruger JP. Micro-costing studies in the health and medical literature: protocol for a systematic review. Syst Rev. 2014 May 21;3:47. doi: 10.1186/2046-4053-3-47.
Reference Type
RESULT
Scott CA, Iyer H, Bwalya DL, McCoy K, Meyer-Rath G, Moyo C, Bolton-Moore C, Larson B, Rosen S. Retention in care and outpatient costs for children receiving antiretroviral therapy in Zambia: a retrospective cohort analysis. PLoS One. 2013 Jun 28;8(6):e67910. doi: 10.1371/journal.pone.0067910. Print 2013.
Reference Type
RESULT
Fatti G, Ngorima-Mabhena N, Tiam A, Tukei BB, Kasu T, Muzenda T, Maile K, Lombard C, Chasela C, Grimwood A. Community-based differentiated service delivery models incorporating multi-month dispensing of antiretroviral treatment for newly stable people living with HIV receiving single annual clinical visits: a pooled analysis of two cluster-randomized trials in southern Africa. J Int AIDS Soc. 2021 Oct;24 Suppl 6(Suppl 6):e25819. doi: 10.1002/jia2.25819.
Reference Type
DERIVED
Lopes J, Grimwood A, Ngorima-Mabhena N, Tiam A, Tukei BB, Kasu T, Mahachi N, Mothibi E, Tukei V, Chasela C, Lombard C, Fatti G. Out-of-Facility Multimonth Dispensing of Antiretroviral Treatment: A Pooled Analysis Using Individual Patient Data From Cluster-Randomized Trials in Southern Africa. J Acquir Immune Defic Syndr. 2021 Dec 15;88(5):477-486. doi: 10.1097/QAI.0000000000002797.
Reference Type
DERIVED
Tukei BB, Fatti G, Tiam A, Ngorima-Mabhena N, Tukei VJ, Tshabalala I, Sejana VM, Muzenda T, Mokoroane LM, Sehlabo L, Maotoe T, Mirembe JK, Membe I, Akpan F, Maile K, Faturiyele I, Xulu T, Minior T, Sanne I, Chasela C; for EQUIP Health. Twelve-Month Outcomes of Community-Based Differentiated Models of Multimonth Dispensing of ART Among Stable HIV-Infected Adults in Lesotho: A Cluster-Randomized Noninferiority Trial. J Acquir Immune Defic Syndr. 2020 Nov 1;85(3):280-291. doi: 10.1097/QAI.0000000000002439.
Reference Type
DERIVED
Faturiyele IO, Appolinare T, Ngorima-Mabhena N, Fatti G, Tshabalala I, Tukei VJ, Pisa PT. Outcomes of community-based differentiated models of multi-month dispensing of antiretroviral medication among stable HIV-infected patients in Lesotho: a cluster randomised non-inferiority trial protocol. BMC Public Health. 2018 Aug 29;18(1):1069. doi: 10.1186/s12889-018-5961-0.
Reference Type
DERIVED
Related Links
Access external resources that provide additional context or updates about the study.
http://www.unaids.org/en/regionscountries/countries/lesotho
UNAIDS. Lesotho: HIV and AIDS estimates.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ID49-2017
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
A Multicentre Trial of Second-line Antiretroviral Treatment Strategies in African Adults Using Atazanavir or Lopinavir/Ritonavir
NCT01255371
WITHDRAWN
PHASE3
Nine Month Course of Anti-HIV Medications for People Recently Infected With HIV
NCT00090779
TERMINATED
PHASE2
Adjusting Antiretroviral Therapy Dosage Using Therapeutic Drug Monitoring
NCT00836212
UNKNOWN
PHASE4
Tenofovir-lamivudine-dolutegravir Combination as Second-line ART: a Randomised Controlled Trial
NCT03991013
COMPLETED
PHASE2
Safety and Efficacy of E/C/F/TDF Versus RTV-Boosted ATV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment-Naive Women
NCT01705574
COMPLETED
PHASE3
Raltegravir and Atazanavir Dosing Strategy Study
NCT00874523
COMPLETED
PHASE3
Safety Study of Raltegravir in HIV/HCV Co-infected Patients
NCT01225705
WITHDRAWN
PHASE4
Efficacy of Simplified Two Drug Kaletra Regimen vs. Kaletra Triple Drug Standard of Care Regimen in Treatment naïve HIV Infected Patients
NCT00234910
COMPLETED
PHASE3
Sustained Virological Suppression and Improvement of Adverse Events of Switching to Raltegravir Study
NCT01679964
COMPLETED
PHASE4
Efficacy of Rilpivirine-based Regimens as Switch Therapy From Nevirapine-based Regimens in HIV-infected Patients
NCT03664440
COMPLETED
NA
Effectiveness of ABT-378/Ritonavir Plus Lamivudine Plus Efavirenz Plus Tenofovir DF in HIV-Infected Patients
NCT00038220
COMPLETED
PHASE2
Comparison of Two Dosing Regimens of GW433908/Ritonavir Versus Lopinavir/Ritonavir for 48 Weeks in HIV Patients Who Have Taken Protease Inhibitors and Experienced Virological Failure
NCT00025727
UNKNOWN
PHASE3
Atazavanir/Ritonavir-based HAART in Children
NCT01656109
COMPLETED
PHASE2
Equivalence of Boosted Atazanavir Based Regimens and Currently Effective HAART Regimens
NCT00940771
COMPLETED
PHASE4
Open-Label Study Comparing Efficacy and Safety of ATV/RTV+3TC With ATV/RTV+TDF/FTC in HIV-Infected, Treatment Naïve Subjects, Followed by Treatment With ATV/RTV+3TC
NCT01620944
TERMINATED
PHASE3
Pilot Study of a Raltegravir Based NRTI Sparing Regimen
NCT00814879
COMPLETED
NA
Levels of Raltegravir in the Female Genital Tissue
NCT01327482
COMPLETED
NA
Atazanavir/Ritonavir, Once Daily + Raltegravir, Twice Daily, Switch Study in HIV-1-Infected Patients
NCT01332227
COMPLETED
PHASE4
Pharmacokinetics, Pharmacodynamics and Cervicovaginal Lavage of Combined Oral Contraceptives and Raltegravir
NCT01597180
WITHDRAWN
Efficacy of Atazanavir/Ritonavir Monotherapy as Maintenance in Patients With Viral Suppression
NCT01511809
COMPLETED
PHASE3
Maintenance Boosted Lopinavir Monotherapy Following Salvage Protease-inhibitor (PI) Based Regimen in HIV With Non-nucleoside Reverse Transcriptase Inhibitors (NNRTI) Based Regimen Failure
NCT01189695
COMPLETED
PHASE4
TDM of Generic Lopinavir/Ritonavir 200/50 mg
NCT00802334
COMPLETED
PHASE2
A Dose-Frequency Trial of Oral Retrovir in Patients With AIDS or Severe ARC
NCT00002046
COMPLETED
NA
Comparing Standard-Dose Versus Adjusted-Dose Lopinavir/Ritonavir Therapy in HIV-Infected Persons With Drug Resistance
NCT00046033
COMPLETED
PHASE2
Trial of an Alternative Dosing Regimen of Oral Retrovir in Patients With AIDS or Advanced ARC
NCT00002020
COMPLETED
NA